9th May 2014 - New research
J.Dickson, Z.Kefalopoulou, A.Djamshidian, J.Kahan, P.E.Fmedsci, P.Whitton, R.Wyse, T.
Isaacs, A.Lees, P.Limousin, T.Foltynie)
Exenatide, which is a treatment for diabetes, has been tested as a disease modifying treatment
for Parkinson's Disease. Exenatide is an injected glucagon-like peptide-1 agonist medication
marketed as Byett and Bydureon and is used in the treatment of insulin resistance in patients
with Type 2 diabetes. It differs in pharmacological action and chemical structure from
insulin. For more information go to : http://www.rxlist.com/byetta-drug.htm
The authors do not suggest how this diabetes drug can have effect in Parkinson's Disease.
Using the MDS-UPDRS, which is a means of assessing the
extent of Parkinson's Disease symptoms, people with
Parkinson's Disease were assessed who had previously taken
Exenatide. People with Parkinson's Disease had an advantage
of 5.6 points (with a range of 2.2 to 9.0) on the assessment.
They also had a better score when assessed concerning
dementia. Unusually, the effect of Exenatide on Parkinson's
Disease had continued beyond its use.
In a previous study, when people with moderate Parkinson's Disease received subcutaneous
injections of Exenatide for a year there were marginal improvements in Parkinson's Disease
motor and cognitive measures. Exenatide treated patients had a mean improvement after one
year on the UPDRS of 2.7 compared with a mean decline of 2.2 points in controls. Exenatide
was well tolerated but weight loss was common.
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/23728174http://www.viartis.net/parkinsons.disease/news/140509.pdf